Authors/Disclosures
|
Martin Weber, MD
(Universitätsmedizin Göttingen)
|
Dr. Weber has nothing to disclose. |
|
|
No disclosure on file |
|
Talyta Grippe, MD
(University of Health network)
|
Dr. Grippe has nothing to disclose. |
|
Thomas E. Prod'Homme, PhD
(Momenta Pharmaceuticals)
|
No disclosure on file |
|
|
No disclosure on file |
|
Marwa Elamin, MD
(University College Hospital Galway)
|
Dr. Elamin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Denise Diniz Carneiro
|
Denise Diniz Carneiro has nothing to disclose. |
|
Olaf Stuve, MD, PhD, FAAN
(UT Southwestern Medical Center)
|
Dr. Stuve has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurological Diseases. Dr. Stuve has received research support from US Department of Veterans Affairs. Dr. Stuve has received research support from National Multiple Sclerosis Society (US). Dr. Stuve has received research support from Merck KGaA. |
|
|
No disclosure on file |
|
Natalia S. Cunha, MD
(SHS Qd 2)
|
Dr. Cunha has nothing to disclose. |
|
Scott S. Zamvil, MD, PhD, FAAN
(University of CA, San Francisco)
|
Dr. Zamvil has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Zamvil has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. The institution of Dr. Zamvil has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Zamvil has received research support from Sumaira Foundation. Dr. Zamvil has received personal compensation in the range of $5,000-$9,999 for serving as a Advisory Board with Genzyme. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Genentech. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Alexion. |
|
Peter Bede, MD, PhD
(Academic Unit of Neurology)
|
Dr. Bede has nothing to disclose. |
|
|
No disclosure on file |
|
Mark T. D'Esposito, MD, FAAN
(University of California)
|
No disclosure on file |
|
|
No disclosure on file |
|
Carlos Bernardo Tauil, MD, FAAN
(University of Brasilia)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Niall Pender, PhD
|
No disclosure on file |
|
Orla Hardiman, MD, FRCPI, FAAN
(Trinity Biomedical Sciences Institute)
|
Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Pharmaceuticals. Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics . Dr. Hardiman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hardiman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Taylor and Francis. The institution of Dr. Hardiman has received research support from Science Foundation Ireland. The institution of Dr. Hardiman has received research support from HRB. |